Literature DB >> 23675718

The renin-angiotensin system in pulmonary hypertension.

Nicholas W Morrell, Kurt R Stenmark.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23675718      PMCID： PMC5448512          DOI： 10.1164/rccm.201210-1872LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  7 in total

1.  Angiotensin II activates MAPK and stimulates growth of human pulmonary artery smooth muscle via AT1 receptors.

Authors:  N W Morrell; P D Upton; S Kotecha; A Huntley; M H Yacoub; J M Polak; J Wharton
Journal:  Am J Physiol       Date:  1999-09

2.  Right ventricular angiotensin converting enzyme activity and expression is increased during hypoxic pulmonary hypertension.

Authors:  N W Morrell; S M Danilov; K B Satyan; K G Morris; K R Stenmark
Journal:  Cardiovasc Res       Date:  1997-05       Impact factor: 10.787

3.  Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension.

Authors:  C Orte; J M Polak; S G Haworth; M H Yacoub; N W Morrell
Journal:  J Pathol       Date:  2000-11       Impact factor: 7.996

4.  Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension.

Authors:  Frances S de Man; Ly Tu; M Louis Handoko; Silvia Rain; Gerrina Ruiter; Charlène François; Ingrid Schalij; Peter Dorfmüller; Gérald Simonneau; Elie Fadel; Frederic Perros; Anco Boonstra; Piet E Postmus; Jolanda van der Velden; Anton Vonk-Noordegraaf; Marc Humbert; Saadia Eddahibi; Christophe Guignabert
Journal:  Am J Respir Crit Care Med       Date:  2012-08-02       Impact factor: 21.405

5.  Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension.

Authors:  N W Morrell; E N Atochina; K G Morris; S M Danilov; K R Stenmark
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

6.  Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension.

Authors:  N W Morrell; K G Morris; K R Stenmark
Journal:  Am J Physiol       Date:  1995-10

7.  Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease.

Authors:  Nicholas W Morrell; Matthew A Higham; Peter G Phillips; B Haleema Shakur; Paul J Robinson; Ray J Beddoes
Journal:  Respir Res       Date:  2005-08-01
  7 in total
  4 in total

Review 1.  The Impact of ACE and ACE2 Gene Polymorphisms in Pulmonary Diseases Including COVID-19.

Authors:  Iphigenia Gintoni; Maria Adamopoulou; Christos Yapijakis
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

2.  Elevated pulmonary arterial and systemic plasma aldosterone levels associate with impaired cardiac reserve capacity during exercise in left ventricular systolic heart failure patients: A pilot study.

Authors:  Bradley A Maron; Thomas E Stephens; Laurie A Farrell; William M Oldham; Joseph Loscalzo; Jane A Leopold; Gregory D Lewis
Journal:  J Heart Lung Transplant       Date:  2015-10-19       Impact factor: 10.247

Review 3.  Estradiol Metabolism: Crossroads in Pulmonary Arterial Hypertension.

Authors:  Stevan P Tofovic; Edwin K Jackson
Journal:  Int J Mol Sci       Date:  2019-12-23       Impact factor: 5.923

4.  Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients.

Authors:  Fengming Huang; Jing Guo; Zhen Zou; Jun Liu; Bin Cao; Shuyang Zhang; Hui Li; Wei Wang; Miaomiao Sheng; Song Liu; Jingcao Pan; Changjun Bao; Mei Zeng; Haixia Xiao; Guirong Qian; Xinjun Hu; Yuanting Chen; Yu Chen; Yan Zhao; Qiang Liu; Huandi Zhou; Jindong Zhu; Hainv Gao; Shigui Yang; Xiaoli Liu; Shufa Zheng; Jiezuan Yang; Hongyan Diao; Hongcui Cao; Ying Wu; Min Zhao; Shuguang Tan; Dan Guo; Xiliang Zhao; Yicong Ye; Wei Wu; Yingchun Xu; Josef M Penninger; Dangsheng Li; George F Gao; Chengyu Jiang; Lanjuan Li
Journal:  Nat Commun       Date:  2014-05-06       Impact factor: 14.919
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.